Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

BACKGROUND: Licensed ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea®; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin®; F. Hoffmann-La Roche AG, Basel, Switzerland) are used to treat macula...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Health Technol Assess
Main Authors: Hykin, Philip, Prevost, A Toby, Sivaprasad, Sobha, Vasconcelos, Joana C, Murphy, Caroline, Kelly, Joanna, Ramu, Jayashree, Alshreef, Abualbishr, Flight, Laura, Pennington, Rebekah, Hounsome, Barry, Lever, Ellen, Metry, Andrew, Poku, Edith, Yang, Yit, Harding, Simon P, Lotery, Andrew, Chakravarthy, Usha, Brazier, John
Formato: Artigo
Idioma:Inglês
Publicado em: NIHR Journals Library 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8287375/
https://ncbi.nlm.nih.gov/pubmed/34132192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta25380
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados